SG Americas Securities LLC Purchases 31,915 Shares of Hims & Hers Health, Inc. (NYSE:HIMS)

SG Americas Securities LLC boosted its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMSFree Report) by 44.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 104,422 shares of the company’s stock after acquiring an additional 31,915 shares during the period. SG Americas Securities LLC’s holdings in Hims & Hers Health were worth $2,525,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Main Management ETF Advisors LLC acquired a new stake in shares of Hims & Hers Health during the third quarter worth about $672,000. Robeco Institutional Asset Management B.V. bought a new stake in Hims & Hers Health during the 3rd quarter worth approximately $604,000. Carnegie Investment Counsel acquired a new stake in Hims & Hers Health during the 3rd quarter worth approximately $5,531,000. Royce & Associates LP lifted its stake in Hims & Hers Health by 17.0% in the third quarter. Royce & Associates LP now owns 341,000 shares of the company’s stock valued at $6,281,000 after buying an additional 49,500 shares in the last quarter. Finally, Versor Investments LP acquired a new position in shares of Hims & Hers Health in the third quarter valued at approximately $634,000. 63.52% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, CEO Andrew Dudum sold 188,888 shares of the stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $20.88, for a total transaction of $3,943,981.44. Following the transaction, the chief executive officer now owns 67,015 shares in the company, valued at approximately $1,399,273.20. This trade represents a 73.81 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Michael Chi sold 2,054 shares of the business’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $33.56, for a total value of $68,932.24. Following the completion of the sale, the insider now owns 184,947 shares of the company’s stock, valued at $6,206,821.32. This trade represents a 1.10 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 1,258,406 shares of company stock valued at $34,513,657 over the last ninety days. 17.71% of the stock is currently owned by company insiders.

Hims & Hers Health Stock Down 0.0 %

Shares of NYSE HIMS opened at $30.89 on Monday. Hims & Hers Health, Inc. has a twelve month low of $8.51 and a twelve month high of $35.02. The company has a market cap of $6.75 billion, a PE ratio of 70.20 and a beta of 1.31. The business’s 50 day moving average price is $28.22 and its two-hundred day moving average price is $22.19.

Hims & Hers Health (NYSE:HIMSGet Free Report) last posted its earnings results on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, topping analysts’ consensus estimates of $0.06 by $0.26. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The business had revenue of $401.56 million for the quarter, compared to analyst estimates of $382.20 million. During the same period in the previous year, the firm earned ($0.04) EPS. The firm’s revenue was up 77.1% compared to the same quarter last year. As a group, research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently commented on HIMS shares. Piper Sandler raised their price objective on shares of Hims & Hers Health from $21.00 to $24.00 and gave the stock a “neutral” rating in a report on Monday, January 6th. Bank of America downgraded Hims & Hers Health from a “buy” rating to an “underperform” rating and dropped their price target for the company from $32.00 to $18.00 in a research note on Thursday, November 14th. BTIG Research began coverage on Hims & Hers Health in a research report on Tuesday, January 7th. They set a “buy” rating and a $35.00 price objective for the company. Morgan Stanley started coverage on Hims & Hers Health in a research report on Tuesday, December 17th. They issued an “overweight” rating and a $42.00 target price on the stock. Finally, Citigroup downgraded Hims & Hers Health from a “neutral” rating to a “sell” rating and upped their price target for the stock from $24.00 to $25.00 in a research report on Friday, January 10th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat, Hims & Hers Health currently has a consensus rating of “Hold” and a consensus price target of $25.13.

Check Out Our Latest Stock Report on Hims & Hers Health

About Hims & Hers Health

(Free Report)

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

See Also

Want to see what other hedge funds are holding HIMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hims & Hers Health, Inc. (NYSE:HIMSFree Report).

Institutional Ownership by Quarter for Hims & Hers Health (NYSE:HIMS)

Receive News & Ratings for Hims & Hers Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hims & Hers Health and related companies with MarketBeat.com's FREE daily email newsletter.